Equities

Arctic Bioscience AS

Arctic Bioscience AS

Actions
Consumer Staples Food Producers
  • Price (NOK)13.50
  • Today's Change2.25 / 20.00%
  • Shares traded8.75k
  • 1 Year change-28.57%
  • Beta--
Data delayed at least 15 minutes, as of Oct 03 2022.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Arctic Bioscience AS is a Norway-based biotech company developing and commercializing both pharmaceutical and nutraceutical products based on the properties of herring roe oil. Arctic Bioscience’s purpose is to provide people with autoimmune disorders an effective and healthy therapy based on marine membrane lipids. The Company is developing HRO350 - a novel investigational drug candidate. HRO350 is being developed for treatment of patients with mild-to-moderate psoriasis. The Company's product portfolio includes, among others, Romega, which is a producer of an omega-3 dietary supplement made from herring roe in a form of a capsule, as well as herring caviar oil and herring caviar protein offered to Business-to-Business (B2B) customers. Arctic Bioscience AS has three subsidiaries Arctic Nutrition AS, Romega AS and Arctic Biopharma AS.

  • Revenue in NOK (TTM)23.95m
  • Net income in NOK-36.30m
  • Incorporated2011
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cereno Scientific AB0.00-19.04m225.63m----1.46-----0.1988-0.19880.001.500.00-------13.47-18.58-15.50-20.82-----------18.990.0326-------1.48--54.51--
Hamlet Pharma AB0.00-9.88m232.28m4.00--8.87-----0.0928-0.09280.000.37090.00-------37.15-78.57-45.89-95.01-----------32.450.00------67.05------
AlzeCure Pharma AB0.00-72.09m240.94m14.00--5.71-----1.76-1.760.000.84610.00----0.00-106.78---127.49--------------0.00-------8.99------
Lipidor AB15.01m-27.87m242.18m----10.37--16.13-0.9806-0.98060.53120.81940.3489--15.07---64.75---75.91-------185.59------0.00--2,380.00---31.39------
Active Biotech AB publ0.00-56.37m250.04m11.00--12.90-----0.2525-0.25250.000.07440.00-------99.01-27.85-119.68-56.59-------472.29---76.420.2212---100.00---54.52------
Magle Chemoswed Holding AB131.64m8.97m252.74m--28.191.7511.761.920.84440.844412.4013.610.57280.57775.97--3.90--5.06--89.35--6.81--0.7295--0.2557---7.16--130.57------
SoftOx Solutions AS6.22m-66.47m269.95m----4.15--43.40-6.68-6.680.6186.290.0732--0.4637---78.20-44.89-95.77-54.35-----1,068.77-540.761.08-116.250.1873---19.69139.15-74.85------
Kancera AB0.00-50.66m276.58m7.00--2.96-----0.918-0.9180.001.690.00----0.00-39.19-68.54-43.09-86.44--92.88---5,941.59---115.850.00---100.00---12.80------
ISR Immune System Rgultn Hldg AB (publ)0.00-252.86m278.20m-----------3.65-3.650.00-2.390.00-------1,169.75-111.37---155.17-----------128,581.00---------152.98------
Arctic Bioscience AS23.95m-36.30m281.54m----0.919--11.76-1.50-1.500.986112.570.06910.62352.68---10.47---11.05--18.34---151.56--8.86-135.400.00--4.97---88.48------
Alligator Bioscience AB18.76m-160.10m285.43m49.00--1.51--15.22-1.27-1.270.12450.87220.0938--2.35414,673.90-80.03-33.26-98.19-36.20-----853.59-672.07----0.0967--197.40-25.981.09---58.36--
SenzaGen AB29.82m-30.42m286.32m16.00--2.97--9.60-1.26-1.261.244.070.28414.465.66---28.98-25.56-32.24-27.4763.32130.22-102.02-471.453.51--0.0092--93.7998.69-15.38---23.45--
Herantis Pharma Oyj0.00-111.88m330.44m----16.13-----0.8301-0.83010.000.11350.00-------110.52-65.71-198.51-79.09-----------6.650.7896-------39.49------
Vo2 Cap Holding AB (publ)371.22m-5.24m335.22m----1.9249.220.903-0.323-0.3239.093.611.93--12.51---2.72-31.87-3.80-57.9521.3726.64-1.41-19.29--5.260.1680--46,310.78185.46-246.86------
Initiator Pharma A/S0.00-61.40m358.37m----11.99-----1.40-1.400.000.58160.00-------124.45-70.46-139.58-80.40------------0.4185-------142.20------
Mendus AB (publ)1.76m-114.66m362.33m34.00--0.6138--205.40-0.5836-0.58360.0093.010.0025--0.094359,800.00-16.00-23.81-16.48-26.35-----6,499.94-----31.270.0418-------49.48------
Data as of Oct 03 2022. Currency figures normalised to Arctic Bioscience AS's reporting currency: Norwegian Krone NOK

Institutional shareholders

9.91%Per cent of shares held by top holders
HolderShares% Held
Fj�rde AP-fondenas of 30 Jun 20221.20m4.92%
Storebrand Asset Management ASas of 31 May 20221.02m4.17%
Cicero Fonder ABas of 31 Aug 2022113.32k0.47%
Equinor Asset Management ASAas of 30 Jun 202285.00k0.35%
More ▼
Data from 30 Jun 2022 - 31 Aug 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.